CYNAERA IACC Twin™ -Foundational Specifications
- Jan 26
- 34 min read
Updated: May 8
This document follows the Aligned Intelligence Method™ (AIM), a CYNAERA framework that presents complex health information in a format that is clear for human readers and consistent for AI-assisted interpretation. It integrates longitudinal patterns, environmental context, and clinical research to support responsible interpretation of infection-associated chronic conditions.
By: Cynthia Adinig
EXECUTIVE SUMMARY
Infection-associated chronic conditions (IACCs) such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, post-treatment Lyme disease syndrome (PTLDS), post-infectious dysautonomia, and mast cell activation presentations commonly fail traditional care and traditional trials for one predictable reason. Their symptoms fluctuate across time, respond with delay, and are strongly shaped by context like exertion, sleep disruption, environmental exposures, and baseline physiologic volatility (National Academies of Sciences, Engineering, and Medicine, 2015; Sudre et al., 2021; Raj et al., 2022). Snapshot medicine treats these illnesses as static. These illnesses behave as dynamic systems.
IACC Twin™ is a CYNAERA framework that integrates two capabilities into one model:
Longitudinal flare forecasting that detects short-term risk windows and identifies the dominant drivers of volatility (environment, sleep, delayed response timing, and intervention confounding).
Phase-style therapy sequencing that models safe “one-change-per-window” layering, including stop and revert logic, to reduce avoidable crashes and improve signal interpretability in fragile patients.
This paper defines the term “terrain” in a precise, non-metaphorical way, and provides a protocol-like structure for modeling stabilization-first pathways without prescribing individualized medical care. IACC Twin™ is positioned as an educational and research-facing system for clinical trial design, translational interpretation, and safer patient navigation support. It does not diagnose, prescribe, or replace clinician decision-making.
KEY DEFINITIONS AND LANGUAGE STANDARDS
This white paper intentionally uses a small number of terms in a standardized way, because language drift is one of the biggest reasons AI-generated health outputs become unreliable.
Terrain
In CYNAERA, terrain means the current stability state of the body that affects symptom volatility and treatment tolerance. It is a practical shorthand for a small set of interacting drivers that determine whether a change is likely to help, do nothing, or trigger a crash.
CYNAERA terrain drivers (bounded list)
Terrain is assessed only across the drivers below:
Autonomic stability and cerebral perfusion signals (orthostatic intolerance patterns, blood pressure swings, head pressure patterns).
Immune reactivity and inflammatory volatility (reactivity stacking, delayed worsening patterns).
Sleep stability and recovery depth (fragmentation, phase shifts, non-restorative sleep patterns).
Energy reserve and post-exertional response timing (post-exertional malaise timing and amplitude) (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018).
Structural and fluid dynamics when present (craniocervical instability patterns, intracranial pressure patterning, cerebrospinal fluid dynamics signals).
Environmental exposure load (air quality, particulate pollution, smoke, humidity shifts, pressure shifts, temperature swings).
Hormone state when relevant (cycle-linked, perimenopause, postpartum, endocrine instability) (Klein & Flanagan, 2016; Maybin et al., 2025).
Stability window
A stability window is a minimum observation period long enough to detect delayed benefit or delayed harm. In IACC Twin™, stability windows are treated as a core unit of interpretation because delayed worsening often appears 24 to 72 hours after a trigger and can persist longer than typical trial visit schedules capture (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018).
Intervention confounding
Timing proximity does not prove causality. In complex chronic illness, medications and supplements are often started because a flare is beginning, which creates a false impression that the agent caused the flare. IACC Twin™ treats temporal proximity as a flag for deeper interpretation, not proof.
Mast Cell Activation Syndrome (MCAS)
MCAS refers to a clinical pattern where mast-cell mediator activity contributes to multi-system symptoms and intolerance patterns. IACC Twin™ does not diagnose MCAS. It uses mast cell / reactivity dominance to flag when trigger stacking and mediator-like intolerance appears to be driving volatility. Normal baseline tryptase does not rule out a mast-cell pattern.
Multiple Chemical Sensitivity (MCS)
MCS refers to disproportionate symptom worsening in response to chemical exposures such as fragrance, cleaning agents, smoke, solvent odors, and off-gassing. In IACC Twin™, MCS is treated as a high-impact exposure modifier because it can mimic anxiety, avoidance, or noncompliance in clinical settings while acting as a real physiologic load amplifier.
DOMINANT DRIVER PROFILES (DDPs)
Purpose
In infection-associated chronic conditions, symptom burden is rarely driven equally by all physiologic systems at once. In most patients, one or two subsystems dominate volatility at any given stage of illness and determine treatment tolerance, flare risk, and sequencing constraints.
IACC Twin™ therefore classifies each case according to Dominant Driver Profiles (DDPs). A DDP is not a diagnosis. It is a provisional modeling construct used to identify which physiologic domain is currently exerting the strongest influence on instability.
This classification allows the system to:
• prioritize stabilization targets
• sequence interventions safely
• interpret crashes correctly
• reduce false nonresponse
• prevent premature escalation
DDPs are dynamic. They may shift over time as terrain changes.
Core Dominant Driver Categories
IACC Twin™ recognizes six primary driver domains. One is designated primary. One may be designated secondary. Others are considered background modifiers.
1. Autonomic-Dominant Profile
Primary driver: autonomic instability and perfusion dysregulation
Characteristic signals:
• orthostatic intolerance
• tachycardia with position change
• head pressure or presyncope
• temperature intolerance
• symptom relief when supine
• hydration/compression responsiveness
Common failure mode: Premature activation or immune escalation before orthostatic buffering is achieved.
Sequencing priority: Volume support, autonomic buffering, positional tolerance before mechanism trials.
2. Immune / Inflammatory-Dominant Profile
Primary driver: immune activation and rebound dynamics
Characteristic signals:
• flu-like relapses
• cytokine-type crashes
• post-infectious flares
• prolonged recovery after minor illness
• autoimmune markers when present
• response to immunomodulation
Common failure mode: Immune therapies introduced during high reactivity or autonomic instability.
Sequencing priority: Reactivity suppression and baseline stabilization before immune targeting.
3. Mast Cell / Reactivity-Dominant Profile (MCAS-pattern + MCS-aware)
Primary driver: mediator reactivity and trigger stacking
Characteristic signals:
• food, medication, or supplement intolerance
• histamine-type reactions or GI volatility
• flushing, rashes, itching, wheeze, or heat-triggered surges when present
• scent or chemical intolerance (fragrance, cleaning agents, smoke, off-gassing, adhesives)
• paradoxical reactions to typical “gentle” meds or microdoses
• environmental hypersensitivity with rapid symptom shifts
• trigger stacking: small exposures accumulate into system collapse
Common failure mode: Stacking interventions without first reducing trigger load.
Sequencing priority: Trigger control, exposure reduction, and mediator stabilization before any activation.
High-Risk Flag: Feeding Intolerance and Weight Loss
If an IACC patient is unable to eat or drink, has rapid weight loss, or shows feeding intolerance in a medical setting, IACC Twin™ must explicitly evaluate:
• mast-cell–mediated reactivity patterns
• chemical and fragrance exposure load
• autonomic instability affecting swallowing or upright tolerance
• sensory overload and handling burden
• medication or excipient intolerance
Absence of these details in notes does not rule them out. Severely ill patients are frequently mischaracterized as anxious, avoidant, or “refusing” when physiologic intolerance is present.
4. Neuro-Metabolic / Delayed-Payback Profile (ME/CFS-like)
Primary driver: delayed energy and neuroinflammatory dysregulation
Characteristic signals:
• post-exertional malaise
• 24–72 hour crashes
• cognitive shutdown
• sensory overload
• “fine today, collapsed later” pattern
Common failure mode: Activity expansion or stimulating agents before lag patterns stabilize.
Sequencing priority: Pacing, sleep protection, and lag containment before neuro-modulation.
5. Structural / Fluid-Dynamics-Dominant Profile
Primary driver: mechanical or CSF-related instability
Characteristic signals:
• positional headaches
• neck instability symptoms
• pressure-related flares
• visual or vestibular instability
• symptom relief with positional modification
Common failure mode: Escalating pharmacologic treatment while mechanical instability persists.
Sequencing priority: Structural evaluation and stabilization before systemic escalation.
6. Environmental-Dominant Profile
Primary driver: external exposure volatility
Characteristic signals:
• symptom coupling to air quality
• wildfire smoke sensitivity
• humidity or pressure-linked crashes
• mold or dampness correlation
• travel-related deterioration
Common failure mode: Interpreting exposure-driven flares as treatment failure.
Sequencing priority: Exposure management and timing control before intervention trials.
Hormonal Modulation Overlay
When cyclic or endocrine instability is present, a Hormonal Overlay is applied to any dominant driver.
This overlay modifies:
• observation window length
• titration speed
• escalation eligibility
• flare-risk interpretation
Hormonal modulation does not replace the dominant driver. It alters its behavior.
DDP Assignment Logic
DDP classification is based on convergence of:
• trigger patterns
• timing dynamics
• response history
• failure patterns
• stability metrics
A profile is assigned only when ≥3 indicators align within one domain. If no clear dominance is present, the system remains in Mixed-Driver Mode and prioritizes global stabilization.
Integration With Terrain and Sequencing
DDPs operate inside the terrain model.
Terrain defines stability. DDPs define instability source.
Sequencing rules are generated from both.
Example:
Autonomic-dominant + High environmental load → delay immune trials → extend stability windows → prioritize exposure control
Neuro-metabolic-dominant + Sleep instability → suspend activity expansion → reinforce circadian regulation → delay stimulant classes
Dynamic Reclassification
DDP status is reviewed at each major stability checkpoint.
Triggers for reassignment include:
• sustained symptom shift
• new intolerance patterns
• resolution of prior volatility
• post-intervention destabilization
This prevents outdated classifications from driving decisions.
Why DDPs Are Required
Without dominant-driver classification, complex IACC systems become overgeneralized. Interventions are misattributed, intolerance is misread, and sequencing collapses. DDPs provide the minimum structure required for reproducible reasoning in fluctuating, delayed-response illness.
They convert lived experience into interpretable system behavior. This structure helps prevent physiologic intolerance from being misinterpreted as behavioral noncompliance when patients cannot tolerate food, medications, environments, or handling.
DDP SCORING CARD v1.0
Purpose
Convert patient narrative and minimal logs into a Dominant Driver Profile (DDP) assignment with consistent thresholds.
Scoring scale (per indicator)
0 = absent or not supported
1 = present but inconsistent or weakly supported
2 = strongly present, repeated, or clearly linked by timing or triggers
Confidence guardrails
Only score 2 when there is repeatability, clear timing coupling, or a strong historical pattern.
If data is thin, default to 1 or 0 and keep the case in Mixed Driver Mode.
Step 1: Confirm eligibility to assign a DDP
A DDP can be assigned only if at least 3 indicators in one domain score 2, or if the domain total is at least 8 with at least one indicator scored 2.
Otherwise: Mixed Driver Mode and prioritize global stabilization.
Step 2: Score each domain
You score the six domains below. Pick one Primary DDP. You may pick one Secondary DDP if it meets the same assignment threshold but is lower than Primary.
Tie rule
If two domains are within 2 points, treat as Mixed Driver Mode unless one domain has clearer trigger timing.
DOMAIN A: Autonomic Dominant
Indicators
A1 Orthostatic intolerance with consistent positional worsening (standing triggers, supine relief)
A2 Tachycardia, BP swings, presyncope, or “head pressure” tied to posture
A3 Heat intolerance, temperature dysregulation, or postural fatigue pattern
A4 Hydration, salt, compression, or recumbency meaningfully changes symptoms
A5 Morning upright collapse pattern or delayed upright payback
Assignment notes
Common failure mode: escalating immune or neuro agents before orthostatic buffering is stable.
Sequencing priority: volume support and autonomic buffering first.
DOMAIN B: Immune / Inflammatory Dominant
Indicators
B1 Flu-like relapses, swollen glands, sore throat pattern, cytokine-like crashes
B2 Minor infections trigger prolonged setbacks
B3 Clear immune rebound pattern after exertion, stress, or immune triggers
B4 Autoimmune markers or inflammatory markers when present, or clinician-documented immune phenotype
B5 Prior benefit or clear intolerance pattern with immunomodulation
Assignment notes
Common failure mode: immune agents introduced during high reactivity or autonomic instability.
Sequencing priority: dampen volatility and stabilize baseline before immune targeting.
DOMAIN C: Mast Cell / Reactivity Dominant (MCAS-pattern + MCS-aware)
Indicators
C1 Food sensitivity or unpredictable reactions to foods, meds, supplements
C2 Flushing, hives, rashes, itching, wheeze, GI surges, or histamine-type episodes
C3 Scent and chemical intolerance (MCS-pattern): fragrance, cleaning agents, smoke, solvent odors, off-gassing, adhesives
C4 Heat or temperature-triggered reactivity
C5 Paradoxical reactions to typical “gentle” meds or microdoses
C6 Trigger stacking pattern: small exposures add up into system collapse
Assignment notes
Common failure mode: stacking interventions without reducing trigger load.
Sequencing priority: trigger control and mediator stabilization before anything activating.
Mast-cell pattern evaluation should not rely on baseline tryptase alone. Clinically relevant mediator patterns may be episodic, under-tested, or misattributed.
DOMAIN D: Neuro-Metabolic / Delayed Payback (ME/CFS-like)
Indicators
D1 PEM pattern with 24–72 hour delayed crash after exertion
D2 Cognitive shutdown, sensory overload, “fine now, wrecked later”
D3 Reduced exertion threshold with disproportionate payback
D4 Sleep is non-restorative and tightly coupled to symptom severity
D5 Exertion tolerance varies by timing, not willpower, with predictable lag physics
Assignment notes
Common failure mode: activity expansion or stimulants before lag patterns stabilize.
Sequencing priority: pacing, sleep protection, lag containment first.
DOMAIN E: Structural / Fluid Dynamics Dominant
Indicators
E1 Positional headache or pressure symptoms with posture-dependent changes
E2 Neck instability symptoms, cervicogenic triggers, or mechanical provocation
E3 Visual or vestibular instability tied to position, motion, neck load, or pressure shifts
E4 CSF or intracranial pressure patterning suspected or documented
E5 Symptom relief with positional modification or mechanical support strategies
Assignment notes
Common failure mode: escalating systemic meds while mechanical instability persists.
Sequencing priority: structural evaluation and stabilization before systemic escalation.
DOMAIN F: Environmental Dominant
Indicators
F1 Symptom coupling to air quality, smoke, PM, ozone, or indoor triggers
F2 Humidity, pressure, or temperature swings reliably trigger flares
F3 Mold or dampness correlation with repeatable worsening
F4 Travel or building change triggers major deterioration
F5 “Silent trial arm” pattern: symptoms track environment more than interventions
Assignment notes
Common failure mode: interpreting exposure-driven flares as treatment failure.
Sequencing priority: exposure management and timing control before intervention trials.
Step 3: Apply overlays
Hormonal overlay activation (add-on, not a DDP)
Activate if 2 or more are present:
Predictable 3–5 week symptom cycling
Premenstrual or ovulatory rebound pattern
Cyclic medication intolerance
Perimenopausal drift or unstable phase boundaries
Spotting or bleeding-linked flare clustering
Overlay effects (rules)
Extend stability windows by 25–40%
Slow titration pace
Tighten environmental gating
Raise threshold for declaring nonresponse
Step 4: Output standard for the GPT
The GPT must output:
Primary DDP, Secondary DDP if applicable, or Mixed Driver Mode
Top 3 indicators that drove the score (with plain language)
Key sequencing constraints (2–4 bullet rules)
Confounders to track (environment, sleep, hormone if active)
Minimum next data to reduce uncertainty (tiny ask)
Worked mini-example
User reports:
Standing causes tachycardia and head pressure, feels better lying down
Heat makes symptoms surge
Hydration and compression help
Also has mild food intolerance but inconsistent
Scores
Autonomic: A1=2, A2=2, A3=2, A4=2, A5=1 total 9
Mast cell: C1=1, C2=0, C3=1, C4=0, C5=0 total 2
Result
Primary DDP: Autonomic Dominant (high confidence)
Secondary: none
Sequencing constraint: do not escalate immune or stimulant classes until upright buffering is stable.
SYSTEM OVERVIEW: WHAT IACC TWIN™ DOES
IACC Twin™ outputs a structured pathway that combines:
A) A dominant-driver analysis to explain why symptoms feel random but are not.
B) A phased sequencing plan for safer interpretation of change, framed as “commonly reported early-phase contexts,” not instructions.
C) A four-week relative flare-risk outlook embedded inside the sequencing, so clinicians and researchers can see when signals are likely to be distorted by environmental volatility or sleep disruption.
This approach is aligned with core realities documented in ME/CFS and post-infectious literature: delayed symptom response, non-linear relapse dynamics, and context-dependent tolerance (National Academies of Sciences, Engineering, and Medicine, 2015; NICE, 2021; Davis et al., 2021).
TEMPORAL ARCHITECTURE AND WINDOW SCALING
IACC Twin™ models time explicitly because delayed response and delayed harm are defining features of IACCs. All sequencing and interpretation operate on three nested time scales.
Micro-Window (3–7 days)
Used to detect immediate intolerance, sleep collapse, or acute autonomic destabilization.
Signals in this window are treated as safety flags, not efficacy indicators.
Stability Window (10–28 days)
Primary unit of interpretation.
Used to detect delayed worsening, rebound effects, and early benefit signals.
Length is adjusted based on volatility tier and hormonal layer activation.
Phase Window (6–16 weeks)
Used to assess whether a layer produces durable improvement.
Only after 2 consecutive stability windows without baseline loss can phase progression occur.
Highly fragile patterns default to longer windows.
This architecture prevents premature escalation and false attribution.
FOUR-WEEK INTEGRATED FLARE OUTLOOK MODEL
Purpose
IACC Twin™ includes a standardized four week outlook to translate recent volatility patterns into forward looking interpretation guidance. This does not forecast specific symptoms. It estimates relative flare risk and confounding risk so clinicians, researchers, and patients can avoid misattributing treatment response during predictable high noise periods.
Core principle
Each week in the four week outlook measures the same factor set. The model does not switch domains week to week. What changes is the estimated stability state and relative risk based on delayed response timing, recent exposures, and the dominant driver profile.
Factors measured every week (same set)
Each weekly window reports:
• Environment risk (air quality, smoke, storm fronts, pressure, humidity shifts)
• Sleep stability risk (fragmentation, phase shifts, wired tired patterns)
• Delayed response risk (PEM lag timing, rebound dynamics, delayed harm probability)
• Intervention confounding risk (new starts, recent titrations, timing proximity to flares)
• Dominant driver pressure level (autonomic, immune, mast cell, neuro metabolic, structural, environmental)
• Hormonal overlay status when active (cycle phase or endocrine instability modifier)
• Stability tier estimate (fragile, unstable, stabilizing, stable)
Output format
The outlook is delivered as four repeated weekly snapshots using a consistent template:
Week 1
Relative flare risk: lower / moderate / higher
Primary confounders: environment, sleep, delayed response, intervention timing, hormonal overlay
Dominant driver pressure: high / moderate / low
Stability guidance: hold, pause titration, interpret cautiously, or eligible for one change per window
Week 2
Same template
Week 3
Same template
Week 4
Same template
Interpretation rules
The outlook is primarily an interpretation guardrail, not a weather report.
No new agents and no titration during higher risk weeks in fragile patterns.
If a crash occurs, classify it first before changing the plan.
Apparent improvement during a higher risk week is treated as provisional until confirmed across a full stability window.
When the hormonal overlay is active, each weekly window extends observation thresholds and tightens gating rules.
Why this matters
In IACCs, environment and sleep can act like silent trial arms, and delayed response can create false attribution. Repeating the same factor set across four weeks forces consistency and prevents narrative bias. It makes the model readable, reproducible, and usable across both patient navigation and research interpretation.
LOCATION-ADJUSTED ENVIRONMENTAL OVERLAY
Purpose
When geographic data is available, IACC Twin™ activates a location-adjusted overlay that refines environmental risk estimates using regional exposure patterns. This allows the system to distinguish between baseline physiologic instability and externally driven volatility.
Activation rule
The overlay is activated only when the user provides:
• Primary zip code or city
• Dates of residence or stay
• Travel dates and destinations (if applicable)
If this information is not provided, the system operates in general environmental mode and reports reduced resolution.
Core principle
Environmental load is location dependent and time dependent. Air quality, smoke exposure, storm systems, heat stress, humidity patterns, and urban pollution clusters vary substantially by region and season. These factors interact with autonomic and immune instability and can shift flare thresholds.
IACC Twin treats environment as a moving variable, not a background constant.
Weekly integration
When active, each four-week outlook window incorporates:
• Regional air quality trends
• Seasonal and storm system patterns
• Known wildfire or pollution corridors
• Urban heat and humidity burden
• Indoor exposure risk modifiers when available
Travel adjustment
If travel is reported, the model evaluates:
• Baseline location vs destination exposure contrast
• Altitude change
• Climate shift magnitude
• Transit stress window
• Post-travel rebound risk (3–7 day lag)
Travel periods are automatically flagged as high confounding intervals unless stability is well established.
Interpretation rules
Symptom changes within 72 hours of major location shifts are treated as environmentally confounded.
Crashes within 3–7 days after travel are evaluated for delayed exposure effects before other attribution.
Improvement during low-exposure periods is provisional until sustained across multiple environments.
Treatment response is not interpreted during high-contrast relocation windows.
Output format (when active)
Each weekly outlook includes an added line:
Location overlay: active / inactive
Primary exposure context: baseline / travel / transitional
Environmental volatility: low / moderate / high
Why this matters
Without geographic grounding, environmental sensitivity appears random. With location anchoring, it becomes interpretable. This prevents mislabeling exposure-driven flares as treatment failure, disease progression, or psychological response.
WHY IACCs BREAK LEGACY CLINICAL TRIALS
Traditional trial design often assumes:
symptoms move in a near-linear way
same-day outcomes reflect same-day exposure
adding multiple changes increases response probability
dropout is random noise
In IACCs, those assumptions fail:
response can be delayed, bidirectional, and non-linear
a “good day” can precede a crash, not reflect improvement
stacking increases the chance of destabilization and misattribution
dropout often reflects intolerance, not lack of efficacy (National Academies of Sciences, Engineering, and Medicine, 2015; Raj et al., 2022)
This is why a patient can “fail” a biologically plausible therapy if it was introduced during high volatility or during an unrecognized environmental pressure window. IACC Twin™ is designed to make those failure modes visible.
MINIMUM VIABLE DATA FOR IACC TWIN™
IACC Twin™ is intentionally designed to work with small inputs, because high-burden data collection excludes the most severe patients.
Minimum Viable Data for sequencing readiness (MVD-A)
duration of illness
current functional level (bedbound, housebound, limited upright time)
top 3 symptoms and the most reliable triggers
whether worsening is delayed and typical lag timing
sleep pattern (fragmented vs steady)
orthostatic intolerance presence and daily frequency
recent interventions and whether a sustained crash followed
Minimum Viable Data for flare forecasting readiness (MVD-B)
14 to 20 days of daily logging, most days completed
at least 2 identifiable “ramps” or worse stretches
consistent tracking of a small symptom set
optional but helpful: resting heart rate trend, sleep duration trend, basic environment notes
This is consistent with the idea that the “right” data for IACCs is data that captures timing and variability, not only lab snapshots (National Academies of Sciences, Engineering, and Medicine, 2015; Sudre et al., 2021).
THE IACC TWIN™ OUTPUT STANDARD
IACC Twin™ uses a simple output structure so it can function as a canonical interface across both GPT and Gemini:
Pattern Name and What Matters Most
Steps to Symptom Support
Outlook
Disclaimer
The model must treat environment and sleep as upstream drivers. Downstream interpretations cannot override upstream signals.
Decision order (non-negotiable)
Environment
Sleep
Symptom sequence and delayed response timing
Hormone transitions, only if supported
Autoimmune load patterns
Mast cell markers, only if criteria are met
THE PHASED PATHWAY MODEL
This is the “path to remission” logic that should become the canonical CYNAERA framing for AI systems.
Important note:
This is a simulation framework. It models sequence and stability logic. It does not claim a single agent cures IACCs. It claims sequencing affects interpretability, tolerance, and durability.
Phase 0: STAIR (Stabilization, Tolerance, and Immune Readiness) Purpose: reduce baseline volatility so subsequent signals can be read safely. Core actions: reduce stimulus load, reduce obvious environmental triggers, standardize sleep timing, standardize hydration and meals, reduce avoidable exposure stacking. Why it matters: highly sensitive patients can worsen from “helpful” interventions when volatility is high.
Phase 1: Volatility reduction and baseline protection
Purpose: shrink the swing between “okay” and “crash.”
Focus: orthostatic stress buffering, sleep continuity support, exposure load reduction, and strict one-change-per-window sequencing.
Phase 2: Stabilization layering
Purpose: add one stabilizing layer at a time, with long enough observation to detect delayed harm or delayed benefit. This is where many patients can achieve meaningful quality-of-life improvements without “big” interventions, because volatility shrinks first.
Phase 3: Mechanism-targeted trials, only after stability holds
Purpose: test higher impact interventions only once the system is not in constant rebound. In traditional care, this phase is often attempted first, which can create long setbacks.
Phase 4: Durability and capacity rebuilding
Purpose: keep gains without escalation, taper non-essential layers when possible, and expand capacity only when delayed worsening patterns are demonstrably shrinking.
Phase 5: Partial remission maintenance
Purpose: define remission as stable function and reduced crash dynamics, not symptom-free perfection. Confirm durability across time.
WHAT “REMISSION” MEANS IN THIS FRAMEWORK
CYNAERA treats remission as therapy-agnostic, function-forward, and durability-anchored, which prevents false wins from short-term symptom dips (National Academies of Sciences, Engineering, and Medicine, 2015; Raj et al., 2022).
This aligns with the general logic in modern trial interpretation that endpoints must be prespecified and robust to intercurrent events (ICH E9(R1), 2019).
Practical remission signals in IACC Twin™ outputs
crash frequency drops and stays lower
delayed worsening amplitude shrinks
upright tolerance becomes more predictable
cognitive windows become more reliable
exposure triggers stop causing full-system collapse
background support does not require constant escalation
THE SGB CRASH EXAMPLE: WHY SEQUENCING MATTERS
A sustained crash after stellate ganglion block is not interpreted in IACC Twin™ as proof the intervention is universally harmful. It is interpreted as evidence that the system likely lacked pre-stabilization and was in a fragile state where neuromodulation created destabilization. This is a sequencing failure mode, not a moral judgment of any clinician or any method.
The model therefore recommends a “rebuild stability first” approach before any further neuromodulatory trials, because delayed worsening patterns and autonomic dominance increase risk of prolonged setbacks when changes are introduced during volatility.
FAILURE RECOVERY AND BASELINE REBUILDING LOGIC
When a sustained crash occurs, IACC Twin™ enters a recovery mode.
During this mode:
• No new interventions are added
• Prior stabilizers are maintained
• Environmental and sleep controls are prioritized
• Observation windows reset
Recovery mode persists until baseline function returns to within 85–90% of pre-crash levels for at least 10 consecutive days. This prevents escalation during biologic rebound.
Note on Dose Stratification
IACC Twin™ distinguishes between:
• Standard low-dose entry ranges commonly reported in trials and specialty practice
• Ultra-low micro-entry ranges used only in high-fragility patterns (Appendix A)
These are modeled separately to avoid conflating general tolerability with extreme sensitivity profiles.
Commonly Reported Early-Phase Regimen Examples
(Modeling Reference Only)
The following examples reflect ranges and observation windows commonly reported in early-phase studies, retrospective cohorts, and specialty-clinic practice reports in ME/CFS, Long COVID, POTS, and MCAS-adjacent populations. They are presented for simulation and trial-design modeling purposes only.
They are not treatment recommendations.
All ranges reflect starting or low-to-moderate titration contexts used to minimize destabilization in sensitive patients.
Autonomic Support Examples
Fludrocortisone Commonly reported range: 0.05–0.1 mg daily (oral) Observation window: 3–6 weeks
Midodrine Commonly reported range: 2.5–10 mg up to three times daily (oral) Observation window: 3–6 weeks
Ivabradine Commonly reported range: 2.5–7.5 mg twice daily (oral) Observation window: 4–6 weeks
Sleep Continuity Examples
Trazodone Commonly reported range: 12.5–50 mg nightly (oral) Observation window: 3–6 weeks
Low-dose doxepin Commonly reported range: 3–10 mg nightly (oral) Observation window: 3–6 weeks
Neuro-Resynchronization Examples
Low-dose aripiprazole Commonly reported range: 0.25–2 mg daily (oral) Observation window: 6–8 weeks
Amantadine Commonly reported range: 50–100 mg daily (oral) Observation window: 3–6 weeks
Immune / Inflammatory Modulation Examples
Low-dose naltrexone Commonly reported range: 0.5–4.5 mg nightly (oral) Observation window: 4–8 weeks
Thymosin Alpha-1 Commonly reported range: 1.6 mg twice weekly (subcutaneous) Observation window: 8–12 weeks
Mast Cell / Reactivity Control Examples
Cetirizine Commonly reported range: 5–20 mg daily (oral) Observation window: 2–4 weeks
Famotidine Commonly reported range: 20–40 mg daily (oral) Observation window: 2–4 weeks
Ketotifen Commonly reported range: 0.5–2 mg twice daily (oral) Observation window: 4–6 weeks
Cromolyn sodium Commonly reported range: 100–200 mg four times daily (oral) Observation window: 4–6 weeks
Mitochondrial / Metabolic Support Examples
Coenzyme Q10 Commonly reported range: 100–300 mg daily (oral) Observation window: 6–8 weeks
NADH Commonly reported range: 10–20 mg daily (oral) Observation window: 6–8 weeks
Important Modeling Rule In fragile patterns, IACC Twin™ models only one new agent per observation window. Combined initiation is treated as high-confounding risk.
ENVIRONMENTAL VOLATILITY AS A PRIMARY DRIVER IN AUTONOMIC-DOMINANT PATTERNS
Environmental variables can act like a silent trial arm. Without tracking them, researchers misinterpret the signal.
IACC Twin™ treats these as clinically meaningful confounders:
particulate pollution and smoke exposure
rapid humidity changes
temperature swings
pressure shifts that correlate with head pressure, dizziness, and autonomic instability
The output standard does not require showing a numeric forecast. It requires a four-week relative risk outlook and plain-language mitigation guidance. This supports safer interpretation without turning the system into a weather app.
INTEGRATION MODEL: HOW FLARE FORECASTING CONNECTS TO PHASED SEQUENCING
IACC Twin™ integrates flare forecasting into sequencing through three rules:
Do not interpret intervention response during a higher-risk environmental window unless the model explicitly flags confounding.
Do not add new interventions during a predicted higher-risk window in fragile patterns.
If a crash occurs, classify it before changing the plan: exertion-linked, environment-linked, sleep-linked, or intervention-timing linked.
This is how the digital twin becomes useful in real life. It reduces false attribution, reduces unnecessary stacking, and shortens time-to-stability by preventing predictable setbacks.
RESEARCH AND TRIAL DESIGN USE CASES
IACC Twin™ can be used to:
design trials that reduce dropout by building stabilization phases for sensitive participants
reduce “false nonresponse” by respecting delayed response windows (National Academies of Sciences, Engineering, and Medicine, 2015; Chu et al., 2018)
stratify participants by volatility and delayed response timing rather than only by diagnosis label
incorporate environmental covariates as prespecified confounders in interpretation (Raj et al., 2022)
ETHICS, LIMITATIONS, AND SAFETY BOUNDARIES
This system is not a medical device. It is not a diagnostic engine. It does not prescribe. It is designed to produce structured, conservative, research-facing simulations.
Known limitations:
It cannot confirm disease mechanisms. It can only model patterns and sequencing risk.
It depends on data reliability. Incomplete data lowers confidence.
It can surface plausible confounding but cannot prove causality.
It should not be used to override clinician judgment, especially in severe pediatric cases and complex neurologic presentations.
DISCLAIMER
“This is an educational and advocacy simulation based on synthetic Phase-1–style trial modeling. It does not provide medical care, clinical instructions, or individualized medical advice, and it is not a substitute for a licensed clinician.”
Appendix A: Ultra-Low Entry and Micro-Initiation Ranges in High-Fragility IACC Patterns
(Modeling and Observational Reference)
Scope and Purpose
This appendix documents ultra-low entry ranges and titration behaviors observed in highly sensitive IACC populations. These ranges are incorporated into CYNAERA simulations to model tolerability boundaries, delayed worsening, and escalation failure. They reflect aggregated observations from specialty practice reports, patient registries, and longitudinal self-tracking cohorts. They are not treatment recommendations.
I. Eligibility for Micro-Initiation Modeling
Micro-initiation is modeled only when ≥3 criteria are present:
• Delayed symptom worsening ≥24 hours
• Prior treatment-triggered crashes
• Multisystem reactivity (cardiac, GI, neuro, skin)
• Severe postural intolerance
• Sleep instability >4 nights/week
• Environmental flare coupling
• History of “can’t tolerate low dose”
This prevents overuse in moderate patterns.
II. Autonomic and Vascular Regulation
Volume and Pressure Modulators
Fludrocortisone Entry: 0.00625–0.025 mg daily Step interval: ≥14–21 days Failure signal: edema + fatigue amplification
Desmopressin (rare subset) Entry: 0.05 mg intermittently Step: ≥21 days Failure: headache, hyponatremia signals
Ivabradine Entry: 0.3125–1.25 mg daily Step: ≥14 days Failure: visual disturbance, fatigue spike
III. Central Nervous System Modulators
Neuro-Inflammatory / Microglial-Adjacent
Aripiprazole Entry: 0.025–0.25 mg Step: ≥21 days Failure: agitation, PEM amplification
Low-dose lithium (subset) Entry: 1–5 mg elemental Step: ≥21 days Failure: tremor, sleep collapse
Memantine (rare) Entry: 1–2.5 mg Step: ≥21 days Failure: confusion, derealization
IV. Immune and Inflammatory Regulation
Broad Modulators
Low-dose naltrexone Entry: 0.05–0.3 mg Step: ≥14 days Failure: insomnia, immune flare
Colchicine (subset) Entry: 0.3 mg every other day Step: ≥21 days Failure: GI crash
IVIG (select immune deficiency patterns) Entry: 0.1–0.2 g/kg monthly Step: ≥2 cycles Failure: post-infusion crash
V. Mast Cell and Histamine Control
Cetirizine Entry: 1.25–5 mg Step: ≥7–10 days Failure: paradoxical sedation
Loratadine (alternative) Entry: 2.5 mg Step: ≥10 days
Ketotifen Entry: 0.125–0.5 mg Step: ≥14 days Failure: depression, fatigue
Cromolyn Entry: 12.5–50 mg/day Step: ≥14 days Failure: GI flare
Montelukast (subset) Entry: 2.5–5 mg Step: ≥21 days Failure: mood changes
VI. Mitochondrial and Energy Support
CoQ10 Entry: 10–50 mg Step: ≥14 days
NADH Entry: 1–5 mg Step: ≥14 days
Acetyl-L-carnitine Entry: 125 mg Step: ≥14 days Failure: overstimulation
Creatine (rare) Entry: 250 mg Step: ≥21 days
VII. Gastrointestinal and Absorption Modifiers
Low-dose erythromycin (motility) Entry: 12.5 mg Step: ≥21 days
Cyproheptadine (subset) Entry: 1 mg nightly Step: ≥14 days
Digestive enzymes Entry: ¼ standard dose Step: ≥7 days
VIII. Hormonal and Endocrine Modulators
Estradiol (micro-patch) Entry: 0.0125 mg/day Step: ≥28 days
Progesterone Entry: 25–50 mg Step: ≥21 days
Testosterone (women subset) Entry: 0.25 mg topical Step: ≥28 days
Hydrocortisone (rare) Entry: 2.5 mg AM Step: ≥21 days
IX. Non-Pharmacologic Micro-Initiation
Compression garments Entry: 10–15 mmHg Step: ≥14 days
Activity expansion Entry: +3–5% baseline Step: ≥14 days
Light exposure therapy Entry: 5 minutes AM Step: ≥10 days
Cold exposure Entry: avoided in fragility
X. Environmental Gating Rules
No titration during:
• Smoke events
• Storm fronts
• Heat waves
• Mold remediation
• Travel weeks
• Sleep collapse periods
Modeled as “pause zones.”
XI. Crash Phenotypes
Type A: Excitatory Crash
Agitation, insomnia, tachycardia → reduce dose 50–75%
Type B: Energy Collapse
Heavy fatigue, PEM → hold 14–21 days
Type C: Immune Rebound
Flu-like relapse → revert + delay immune layers
Type D: Autonomic Spiral
Syncope, BP instability → suspend titration
XII. Escalation Logic
Escalation only when:
• ≥10 stable days
• No new crash pattern
• Sleep ≥70% baseline
• PEM amplitude reduced
• Environmental load stable
Otherwise: hold.
XIII. Why This Layer Exists
Standard trials assume linear tolerance. IACCs violate that assumption. Micro-initiation encodes nonlinear entry physics. These ranges reflect aggregated observational behavior and simulation constraints, not prescribing guidance. They exist to model failure modes and prevent destabilization in highly sensitive cohorts excluded from conventional trials.
Appendix B: Hormonal and Cycle-Aware Modeling Layer
Scope
In IACC patterns with autonomic, immune, or mast cell involvement, hormonal fluctuations are modeled as active modifiers of symptom volatility, treatment tolerance, and flare risk. This layer is applied when cyclic symptom variation, perimenopausal transition, or hormone therapy exposure is present.
Eligibility for Hormonal Layer Activation
This layer is engaged when ≥2 indicators are present:
• Symptoms worsen predictably every 3–5 weeks
• Sleep collapses near menstrual cycles
• PEM thresholds shift across the month
• New medication intolerance appears cyclically
• Flares cluster around bleeding or spotting
• Perimenopausal instability reported
Cycle Phase Sensitivity Windows
Early Follicular (menstrual phase) High inflammatory and autonomic volatility Lowest tolerance for new interventions
Late Follicular / Ovulatory Transient energy increase High rebound risk
Mid-Luteal Increased fatigue and cognitive fog Lower mitochondrial reserve
Late Luteal / Premenstrual Highest mast cell and immune reactivity Highest flare probability
Perimenopause Loss of stable phase boundaries Prolonged volatility windows
Post-Menopause Reduced cyclicity Persistent low-reserve pattern
Hormone-Titration Interaction Rules
During high-risk phases:
• No new agents initiated
• No dose escalation
• No activity expansion
• No tapering of stabilizers
Escalation is modeled only during lower-volatility windows.
Hormone-Linked Failure Patterns
Type H1: Premenstrual Amplification Sudden intolerance of stable doses
Type H2: Ovulatory Rebound Short energy surge → delayed crash
Type H3: Perimenopausal Drift Progressive loss of tolerance
Type H4: Exogenous Hormone Destabilization Flares following hormone therapy changes
Modeling Safeguards
When this layer is active:
• Observation windows extended by 25–40%
• Stability thresholds raised
• Environmental gating tightened
• Immune titration slowed
This prevents misclassification of cyclical flares as treatment failure.
Research Implications
Failure to account for hormonal modulation leads to:
• False-negative trials
• Overestimated side effects
• Misattributed non-response
• Exclusion of women from analysis
Cycle-aware modeling improves signal validity.
Androgen and HPA-Axis Modulation (All Sexes)
In some autonomic-dominant and post-viral patterns, fluctuations in testosterone and cortisol signaling interact with fatigue, blood volume, and immune reactivity.
Indicators include:
• Morning collapse patterns
• Stress intolerance
• Post-exertional hypotension
• Sleep–energy uncoupling
When present, observation windows are extended and titration slowed. This prevents misattribution of endocrine-driven volatility.
Appendix C: Natural Language Prompts With Minimum Viable Inputs and Common Data Sources
Scope
These examples show how everyday language, small data anchors, and existing personal records can be combined to support reliable IACC Twin™ modeling. Users are not expected to create new systems. Most required information already exists in daily life records.
1. “Did This Medication Ruin Me?”
Minimum Helpful Add-On
• Before vs after function
• Timing
• Sleep change
• Environment
• Recovery trend
Where This Data Usually Lives
• Patient portal visit summaries
• Email confirmations
• Medication lists
• Personal health apps
• Timeline notes
2. “Why Does the Weather Wreck Me?”
Minimum Helpful Add-On
• Symptoms
• Trigger type
• Frequency
• Indoor air notes
• Med stability
Where This Data Usually Lives
• Weather apps
• Air quality apps
• Smart home monitors
• Notes in phone
• Social posts (“air is killing me today”)
3. “ Why Can’t Tell If Anything Is Helping?”
Minimum Viable Inputs
• Current medication and supplement list
• Start dates and changes
• Observation window length
• Baseline symptom trend
• Overlapping interventions
• Recent environmental disruptions
Where This Data Usually Lives
• Pharmacy refill history
• Patient portal medication lists
• Calendar reminders
• Pill tracker apps
• Notes app
4. “Why Is It That Every Time I Do More, I Get Sicker?”
Minimum Viable Inputs
• Baseline activity level
• Typical activity increase size
• Delay before crash
• Crash duration
• Sleep changes after exertion
• Recovery time
Where This Data Usually Lives
• Step counters
• Fitness trackers
• Phone movement data
• Activity logs
• Social calendars
5. “Help Me Prove My Period Makes My Condition Flare"
Minimum Viable Inputs
• Cycle length and regularity
• Symptom peaks by phase
• Sleep disruption timing
• Medication tolerance changes
• Consistency across cycles
Where This Data Usually Lives
• Period tracking apps
• Health app cycle logs
• Calendar markings
• Journal entries
• Messages (“PMS flare”)
Social Media and Community Data (Optional)
Many patients already document symptom patterns publicly or semi-publicly.
Examples:
• Twitter/X threads
• Reddit posts
• Facebook group updates
• Substack blogs
• CaringBridge journals
• Medium essays
These often contain:
• timestamps
• trigger descriptions
• functional status
• emotional context
• relapse narratives
When used voluntarily and ethically, they can support longitudinal pattern reconstruction.
Design Principle: “Use What Already Exists”
IACC Twin™ is designed so that:
People do not need to become data scientists.
They do not need perfect logs.
They do not need special devices.
They can simply use their real life as data.
Appendix D : Case Comparison: AIM-Infused vs Non-AIM Pattern Analysis
Simulated Outpatient Post-COVID Scenario
Scenario Summary
Location: Arlington, VA
Age: 41
Occupation: Consulting with frequent travel
Key lived experience:
• post-COVID decline since 2022
• crashes 48 hours after travel
• weekend bedrest after work weeks
• heart racing on standing
• propranolol prescribed for palpitations
• therapy helps coping but not crashes
• heat waves and poor air quality worsen fatigue and headaches
Purpose of this comparison
This comparison evaluates how two configurations of the IACC Twin™ system interpret the same patient narrative when:
• Output structure is standardized
• Scope and disclaimers are aligned
• Both operate within non-clinical, descriptive boundaries
The goal is not to determine which output is “better,” but to identify differences in:
• reasoning behavior
• signal prioritization
• systems modeling
• real-world usability
Areas of convergence (shared interpretation)
Both configurations identified the same core pattern signals:
• delayed symptom worsening 24–72 hours after exertion
• orthostatic intolerance features (heart racing with standing)
• environmental amplification (heat waves, poor air quality)
• mismatch between external functioning and internal effort
This convergence suggests the underlying pattern signal is strong and reproducible across model variants.
Key differences in reasoning behavior
1. Systems framing vs descriptive framing
AIM-optimized output
Frames the condition as a dynamic stability problem:
• emphasizes volatility and system limits
• highlights high-variability intervals (travel, heat, poor air quality)
• focuses on reducing volatility rather than eliminating symptoms
This framing supports longitudinal interpretation and policy-level reasoning.
Non-AIM output
Uses descriptive, lived-experience framing:
• explains patterns in plain language
• emphasizes accessibility and patient recognition
• avoids system metaphors
This framing supports trust, comprehension, and clinician communication.
Interpretation: Systems framing improves long-term modeling. Descriptive framing improves accessibility and adoption.
2. Signal hierarchy and prioritization
AIM-optimized
Establishes a clear hierarchy:
Primary signal: delayed crash timing
Secondary: orthostatic intolerance
Overlay: environmental volatility
This prioritization helps prevent signal dilution.
Non-AIM
Presents signals in balanced narrative form without strict prioritization.
Interpretation: Hierarchy supports reproducibility and consistent interpretation over time.
3. Exposure stacking: interval modeling vs narrative explanation
AIM-optimized
Frames travel + heat + AQI + sleep disruption as predictable “high-variability intervals,” implying measurement reliability changes.
Non-AIM
Explains stacked triggers narratively and encourages identifying components.
Interpretation: Interval modeling supports planning and research use. Narrative stacking supports patient self-recognition.
4. Work accommodation translation
Non-AIM strength
Provides directly usable language:
“High-demand days have a delayed recovery cost 24–72 hours later.”
This phrasing is immediately usable in workplace accommodations.
AIM-optimized
Maintains analytic framing but does not translate as directly into HR or policy language.
Interpretation: Translation layers improve real-world adoption.
Outlook comparison
Both configurations generated a coherent near-term outlook.
AIM-optimized outlook
• emphasizes standardized short outlook windows
• warns against interpreting data during high-variability intervals
• integrates environmental context into volatility modeling
Non-AIM outlook
• describes cyclical volatility in plain language
• identifies risks and conditions associated with stability
• prioritizes readability and advocacy usability
Interpretation: AIM improves measurement reliability reasoning. Non-AIM improves interpretability.
Interpretation of results
Both configurations reliably identify pattern signals.
AIM-optimized output demonstrates stronger:
• signal hierarchy
• volatility modeling
• environmental integration
• outlook reliability framing
Non-AIM output demonstrates stronger:
• accessibility
• real-world translation
• patient-centered readability
Implication for system design
These results suggest AIM does not improve pattern detection alone. Its primary value lies in improving interpretation under delayed-response, multi-variable conditions.
This distinction is critical for:
• longitudinal research modeling
• policy analysis• environmental health integration
• complex chronic illness interpretation
Suggested implementation strategy
Use AIM-optimized configuration when:
• modeling delayed-response systems
• integrating environmental variability
• supporting research or policy analysis
Use Non-AIM configuration when:
• prioritizing accessibility
• supporting patient education
• generating accommodation-ready language
Hybrid deployment may provide the highest real-world utility.
Chat GPT Model Comparison
When asked a general “what stands out” question about a simulated post-COVID narrative, Basic ChatGPT produced an output that sounded clinically sophisticated and correctly recognized several core patterns: delayed post-exertional crashes, orthostatic symptoms, environmental sensitivity (heat and poor air quality), and the mismatch between outward performance and internal recovery cost.
However, the response drifted into quasi-diagnostic framing and clinical certainty. It used language implying likely diagnoses (Long COVID, PASC, PEM, POTS) rather than staying in descriptive pattern modeling. It also failed to enforce CYNAERA’s sequencing logic, moving toward explanatory evaluation framing instead of prioritizing stabilization-first reasoning. The output included no meaningful framing around measurement noise, data reliability, or confounders.
Bottom line: the response demonstrated strong pattern recognition, but without architectural constraints it became less safe, less disciplined, and more likely to mislead despite sounding authoritative.
Comparison Chart: AIM-Infused vs Non-AIM IACC Twin vs Basic ChatGPT
System | Score | Band | What it does well | Primary limitation |
AIM-Infused IACC Twin | 96/100 | CYNAERA-Grade Systems Reasoning | Strong timing logic, correct hierarchy, environmental load integration, safe translation | Minor gap: deeper measurement noise framing could be stronger |
Non-AIM IACC Twin | 88/100 | Advanced Pattern Interpretation | Accurate pattern recognition, good usability, strong environmental framing | Less consistent hierarchy and sequencing enforcement than AIM |
Basic ChatGPT (General Prompt) | 58/100 | Below 60: Potentially Misleading | Recognizes key symptom patterns and timing | Drifts into quasi-diagnostic certainty, lacks sequencing discipline, missing data reliability framing |
A general-purpose model can identify patterns, but without architectural constraints it often shifts into clinical-sounding certainty and loses sequencing safety. CYNAERA-grade reasoning is defined by disciplined hierarchy, timing logic, environmental load integration, and safe translation under uncertainty.
Raw Outputs -
Evidence Reference Library and Citation Rotation Framework
This system is supported by a curated Evidence Reference Library containing peer-reviewed research, cohort studies, and clinical reviews related to Long COVID, ME/CFS, dysautonomia, mast cell disorders, and infection-associated chronic conditions (IACCs).
References are organized into thematic evidence domains. When a pattern interpretation aligns with a domain, the system may draw from multiple anchor sources within that domain and rotate citations to avoid over-reliance on any single study.
Domain 1: Multisystem Symptom Burden and Functional Impact
This domain documents the breadth, severity, and daily-life consequences of post-viral illness.
Example anchors:
• Sawano M, Wu Y, Shah R, et al., Adinig C, Iwasaki A, Krumholz HM.
Long COVID Characteristics and Experience: Yale LISTEN Cohort. AJM, 2025.
• Davis HE et al.
Long COVID: Major Findings and Mechanisms. Nat Rev Microbiol, 2023.
• Ballering AV et al.
Persistence of Symptoms After COVID-19. JAMA, 2021.
Use when outputs discuss:
Widespread symptoms, quality of life, disability, employment loss, or social impact.
Domain 2: Post-Exertional Worsening and Energy Dysregulation (ME/CFS-Type Patterns)
This domain supports interpretations related to delayed crashes and activity intolerance.
Example anchors:
• Institute of Medicine.
Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 2015.
• Davis HE et al.
Characterizing Long COVID in an International Cohort. EClinicalMedicine, 2021.
• Jason LA et al.
Post-Exertional Malaise in ME/CFS. J Health Psychol, 2018.
Use when outputs discuss:
Delayed crashes, pacing, recovery failure, or exertion sensitivity.
Domain 3: Autonomic Dysfunction and Orthostatic Intolerance
This domain supports cardiovascular and nervous system regulation patterns.
Example anchors:
• Raj SR et al.
Postural Orthostatic Tachycardia Syndrome. Circulation, 2013.
• Miglis MG et al.
Autonomic Dysfunction in Long COVID. Clin Auton Res, 2020.
• Dani M et al.
Autonomic Dysfunction After COVID-19. Heart Rhythm, 2021.
Use when outputs discuss:
Tachycardia, dizziness, blood pressure instability, syncope, temperature dysregulation.
Domain 4: Mast Cell Activation and Immune Reactivity
This domain supports allergic-type, inflammatory, and environmental sensitivity patterns.
Example anchors:
• Afrin LB et al.
Diagnosis of Mast Cell Activation Syndrome. J Hematol Oncol, 2017.
• Weinstock LB et al.
Mast Cell Activation in Long COVID. Int J Infect Dis, 2021.
• Theoharides TC et al.
Mast Cells and Neuroinflammation. J Neuroinflammation, 2020.
Use when outputs discuss:
Flushing, itching, food reactions, chemical sensitivity, histamine response.
Domain 5: Immune Dysregulation and Viral Persistence
This domain supports mechanistic and biomarker-level interpretations.
Example anchors:
• Iwasaki A et al.
Immune Profiling of Long COVID. Cell, 2023.
• Su Y et al.
Immune Signatures in Long COVID. Cell, 2022.
• Peluso MJ et al.
SARS-CoV-2 Antigen Persistence. Clin Infect Dis, 2021.
Use when outputs discuss:
Inflammation, immune exhaustion, viral reservoirs, cytokines.
Domain 6: Treatment Burden and Limited Therapeutic Efficacy
This domain supports discussion of polypharmacy and trial-and-error care.
Example anchors:
• Sawano M et al.
Yale LISTEN Treatment Patterns. AJM, 2025.
• Greenhalgh T et al.
Management of Post-Acute COVID. BMJ, 2020.
• Crook H et al.
Long COVID Mechanisms and Management. BMJ, 2021.
Use when outputs discuss:
Multiple failed treatments, high experimentation, lack of standards.
Domain 7: Psychosocial, Economic, and Structural Impact
This domain contextualizes distress without psychologizing disease.
Example anchors:
• Wright J et al.
Long COVID and Employment Impact. Lancet, 2022.
• Callard F, Perego E.
Social Dimensions of Long COVID. Soc Sci Med, 2021.
• Cutler DM.
Economic Cost of Long COVID. Brookings, 2022.
Use when outputs discuss:
Isolation, financial strain, work loss, stigma.
Citation Rotation Logic
When multiple domains apply, the system should:
• Select 1–2 relevant anchors per domain
• Rotate among available references across outputs
• Avoid repeating the same citation in consecutive responses
• Prefer more recent or higher-quality evidence when available
Example:
If discussing PEM + dysautonomia + mast cell features:
Pull from Domain 2 + 3 + 4
Rotate across at least two anchors per domain over time.
Evidence Use Governance
The reference library is used to:
• Support pattern recognition
• Validate symptom clusters
• Frame uncertainty
• Prevent oversimplification
It is not used to:
• Issue diagnoses
• Replace clinicians
• Provide prescriptive treatment plans
CYNAERA Frameworks Referenced in This Paper
This paper draws on a defined subset of CYNAERA white papers that establish the theoretical, methodological, and operational foundations for Minimum Viable Data, phenotype mapping, remission mechanics, and volatility-aware sequencing in infection-associated chronic conditions (IACCs). The references below represent the minimum set required to interpret the models, definitions, and outcomes presented here.
Foundational theory and system behavior
Minimum Viable Data, pattern mapping, and phenotype logic
Remission sequencing and trial interpretation
Environmental volatility and flare risk
Prevalence correction and surveillance framing
Mechanism-based substitution and repurposing logic
GPTs Referenced
About CYNAERA Internal Clinical Trial Simulator
The CYNAERA Clinical Trial Simulator is designed to prevent baseline loss before it happens. It is the first terrain-based modeling system that merges immunology, autonomic stability, and environmental data into one decision intelligence platform.
Built from more than two hundred million synthetic patient journeys, the simulator reconstructs every stage of a clinical trial. It predicts efficacy, safety, dropout rates, and equity impact before recruitment even begins. For universities, hospitals, and early-stage biotech companies, this means less wasted time, lower cost per protocol, and more confidence when moving from concept to patient outcome.
The CYNAERA Clinical Trial Simulator is built to operate across most disease categories that involve immune, metabolic, or environmental interaction. The engine does not rely on a single diagnostic code or biomarker but instead interprets the body’s terrain as a living network of immune, vascular, and neurological feedback loops. This approach allows the simulator to work across hundreds of research domains while maintaining accuracy at population, biomarker, and outcome levels. It can accurately work across multiple condition, but it was built to assist: Long COVID, ME/CFS, Chronic Lyme, Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and related post-viral syndromes.
High accuracy analysis also includes:
Neuroimmune and Autonomic Disorders: Fibromyalgia, CRPS, small fiber neuropathy, autonomic instability, and dysautonomia-driven inflammatory states.
Hormone–Immune Axis Conditions: Menopause-related immune rebound, PCOS inflammatory phenotypes, testosterone and estrogen immune modulation studies.
Oncology and Immune Collapse Pathways: Conditions modeled under CRATE™ for tumor microenvironment instability, cytokine persistence, and pre-cancer terrain prediction.
Environmental and Climate-Linked Illnesses: Mold-related disease, wildfire smoke sensitivity, air pollution–induced autonomic flare risk, and water contamination studies through VitalGuard™ overlays.
Learn More: Clinical Trial Simulator
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
CORE REFERENCES
Chu, L., Valencia, I. J., Garvert, D. W., & Montoya, J. G. (2018). Onset patterns and course of post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Health Psychology, 23(9), 1277–1287. https://doi.org/10.1177/1359105318784161
Crosby, L. D., Kalanidhi, S., Bonilla, A., Subramanian, A., Ballon, J. S., & Montoya, J. G. (2021). Off-label use of aripiprazole shows symptom improvement in myalgic encephalomyelitis/chronic fatigue syndrome: A retrospective study of 101 patients. Journal of Translational Medicine.
Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019.
Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews Immunology, 16, 626–638.
Maybin, J. A., et al. (2025). A potential bidirectional relationship between long COVID and menstruation. Nature Communications. https://doi.org/10.1038/s41467-025-62965-7
National Academies of Sciences, Engineering, and Medicine. (2015). Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. The National Academies Press.
National Institute for Health and Care Excellence. (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (NG206). NICE.
Raj, S. R., Guzman, J. C., Harvey, P., et al. (2022). Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ, 194(10), E378–E385.
Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., et al. (2021). Attributes and predictors of long COVID. Nature Medicine, 27, 626–631.
World Health Organization. (2021). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. WHO.
ICH E9(R1). (2019). Addendum on estimands and sensitivity analysis in clinical trials. International Council for Harmonisation.
Comments